PMPaula Muilu

Paula Muilu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Muilu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Hannu Kautiainen

    Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland

    5 shared publications
  • Kari Puolakka

    Terveystalo Healthcare, Lappeenranta, Finland

    5 shared publications
  • Vappu Rantalaiho

    Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Department of Internal Medicine, Kanta-Hame Central Hospital, Hameenlinna, Finland; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

    5 shared publications
  • Vappu Rantalaiho

    Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

    4 shared publications
  • Hannu Kautiainen

    Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland

    3 shared publications
  • Lauri Juhani Virta

    Research Department, Social Insurance Institution of Finland, Turku, Finland

    3 shared publications

Latest Publications

  • Open Access

    Psoriatic arthritis patients have increased morbidity already at the time of diagnosis: a case–control study

    by Anna Laine, Paula Muilu, Hannu Kautiainen, Vappu Rantalaiho

    To evaluate the prevalence of comorbidities preceding the diagnosis of psoriatic arthritis (PsA) compared with the general population. We identified all adult patients granted a special reimbursement (SR) for disease-modifying anti-rheumatic drugs for PsA between 2002 and 2014 from the Finnish Social Insurance Institution register ( N = 6077). Three general population controls were matched to each case. Visits to specialized medical care (Classification of Disease 10th revision coded), and prescription drug purchases categorized by Anatomical Therapeutic Chemical codes were collected for cases and controls between 2000 and 2014. We evaluated the period from 24 months before to 3 months after the index date (ID), defined as the date when the SR was granted. SRs granted for other chronic diseases prior to the ID were additionally collected. PsA patients had three times more visits to specialized medical care and increased overall drug use compared with controls. Based on SRs valid at the time of PsA diagnosis, new-onset PsA patients had significantly higher prevalence of diabetes mellitus (women: 11% vs. 7%; men: 14% vs. 10%; all p < 0.001), cardiovascular diseases (women: 19% vs. 14%; men: 23% vs. 18%; all p < 0.001), and obstructive lung diseases (women: 12% vs. 7%; men: 8% vs. 6%; all p < 0.001) compared with controls. PsA patients demonstrate increased morbidity already at the time of PsA diagnosis. Screening for comorbidities should therefore be considered when joint disease is clinically apparent.

  • Open Access

    Physician global assessment in rheumatoid arthritis—is there any logic?

    by Katriina Jäppinen, Paula Muilu, Reija Autio, Laura Kuusalo, Susanna Sihvonen, Tuulikki Sokka-Isler, Vappu Rantalaiho


  • Open Access

    Pain management, prolonged opioid use, initiated anti-rheumatic treatment and psychiatric morbidity in new-onset psoriatic arthritis

    by Anna Laine, Paula Muilu, Hannu Kautiainen, Kari Puolakka, Vappu Rantalaiho

    Objectives: To explore the use of DMARDs and painkillers in incident PsA patients. Methods: From the Finnish Social Insurance Institution register we collected all adult patients granted a special reimbursement (SR) for DMARDs for PsA from 1 January 2010 to 31 December 2014 (N = 2678). For each case, three general population controls were matched. The purchases of painkillers, antidepressants, anxiolytics and hypnotics were analysed 1 year before and after the index date (ID; the date the SR was granted) and DMARDs at the ID and 1 year before it. Results: The year preceding the ID, 51% of the patients purchased any DMARDs, with 31% being MTX. Nevertheless, on the ID the respective percentages increased to 95% and 71%. PsA patients purchased all painkillers significantly more often than their controls before the ID and the purchases peaked at the ID. After that, the purchases of paracetamol and NSAIDs decreased but those of opioids remained at almost the same level. PsA patients purchased antidepressants and hypnotics more often than their controls. The use of the antidepressants, anxiolytics, hypnotics and opioids before the ID was associated with the risk of prolonged opioid use. Conclusion: A substantial proportion of incident PsA patients are purchasing DMARDs before the ID, which may reflect the difficulty of setting a PsA diagnosis or may represent the treatment of severe skin psoriasis. PsA patients use more painkillers than their matched controls 1 year preceding the diagnosis. Prolonged opioid use is particularly evident among patients using psychiatric medications.


  • Opioid use frequency in early axial spondyloarthritis in Finland – a pharmacoepidemic register study

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri Juhani Virta, Kari Puolakka


  • Open Access

    First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri J. Virta, Johan G. Eriksson, Kari Puolakka

    Background: In this retrospective cohort study, we evaluated the drug therapies used for early rheumatoid (RA) and undifferentiated (UA) arthritis patients. Methods: From a nationwide register maintained by the Social Insurance Institution, information on sex, date of birth, and date of special medicine reimbursement decision for all new Finnish RA and UA patients between 2011 and 14 were collected, and their DMARD (Disease Modifying Antirheumatic Drug) purchases during the first year after the diagnosis were analyzed. Results: A total of 7338 patients with early RA (67.3% female, 68.1% seropositive) and 2433 with early UA (67.8% female) were identified. DMARDs were initiated during the first month after the diagnosis to 92.0% of the patients with seropositive RA, 90.3% with seronegative RA and to 87.7% with UA (p < 0.001). Respectively, 72.1, 63.4, and 42.9% of the patients (p < 0.001) purchased methotrexate; 49.8, 35.9, and 16.0% (p < 0.001) as part of a DMARD combination during the first month. By the end of the first year after the diagnosis, self-injected biologics were purchased by 2.6, 5.3 and 3.1% (p < 0.001) of them. Only 1.4, 2.6 and 3.0% (p < 0.001) of the patients were not receiving any DMARDs. During the first year, 83.4% of the seropositive RA patients had purchased methotrexate, 50.4% sulfasalazine, 72.1% hydroxychloroquine, and 72.6% prednisolone. Conclusions: Currently, combination therapy including methotrexate is a common treatment strategy for early seropositive RA in Finland. Despite an easy access to biologics, these drugs are seldom needed during the first year after diagnosis.


  • Open Access

    First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study.

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri Juhani Virta, Johan Eriksson, Kari Puolakka

    Backgroud: In this retrospective cohort study, we evaluated the drug therapies used for early rheumatoid (RA) and undifferentiated (UA) arthritis patients. Methods: From a nationwide register maintained by the Social Insurance Institution, information on sex, date of birth, and date of special medicine reimbursement decision for all new Finnish RA and UA patients between 2011-14 were collected, and their DMARD (Disease Modifying Antirheumatic Drug) purchases during the first year after the diagnosis were analyzed. Results: A total of 7338 patients with early RA (67.3% female, 68.1% seropositive) and 2433 with early UA (67.8% female) were identified. DMARDs were initiated during the first month after the diagnosis to 92.0 % of the patients with seropositive RA, 90.3% with seronegative RA and to 87.7% with UA (p<0.001). Respectively, 72.1%, 63.4%, and 42.9% of the patients (p<0.001) purchased methotrexate; 49.8%, 35.9%, and 16.0% (p<0.001) as part of a DMARD combination during the first month. By the end of the first year after the diagnosis, self-injected biologics were purchased by 2.6%, 5.3% and 3.1% (p<0.001) of them. Only 1.4%, 2.6% and 3.0% (p<0.001) of the patients were not receiving any DMARDs. During the first year, 83.4% of the seropositive RA patients had purchased methotrexate, 50.4% sulfasalazine, 72.1% hydroxychloroquine, and 72.6% prednisolone. Conclusions: Currently, combination therapy including methotrexate is a common treatment strategy for early seropositive RA in Finland. Despite an easy access to biologics, these drugs are seldom needed during the first year after diagnosis.

  • Open Access

    First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: A nationwide register-based study.

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri Virta, Johan Eriksson, Kari Puolakka

    Backgroud: In this retrospective cohort study, we wanted to evaluate the drug therapies used for early rheumatoid (RA) and undifferentiated (UA) arthritis patients. Methods: From a nationwide register maintained by the Social Insurance Institution, information on sex, date of birth, and date of special medicine reimbursement decision for all new Finnish RA and UA patients between 2011-14 were collected, and their DMARD purchases during the first year after the diagnosis were analyzed. Results: A total of 7338 patients with early RA (67.3% female, 68.1% seropositive) and 2433 with early UA (67.8% female) were identified. DMARDs were initiated during the first month after the diagnosis to 92.0 % of the patients with seropositive RA, 90.3% with seronegative RA and to 87.7% with UA (p<0.001). Respectively, 72.1%, 63.4%, and 42.9% of the patients (p<0.001) used methotrexate; 49.8%, 35.9%, and 16.0% (p<0.001) as part of a DMARD combination during the first month. By the end of the first year after the diagnosis, self-injected biologics were initiated to 2.6%, 5.3% and 3.1% (p<0.001) of them. Only 1.4%, 2.6% and 3.0% (p<0.001) of the patients were not receiving any DMARDs. During the first year, 83.4% of the seropositive RA patients had purchased methotrexate, 50.4% sulfasalazine, 72.1% hydroxychloroquine, and 72.6% prednisolone. Conclusions: Currently, combination therapy including methotrexate is a common treatment strategy for early seropositive RA in Finland. Despite an easy access to biologics, these drugs are seldom needed during the first year after diagnosis.

  • Opioid Use among Patients with Early Inflammatory Arthritides Compared to the General Population

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri Juhani Virta, Kari Puolakka

    Objective.: To assess to what extent the worldwide opioid epidemic affects Finnish patients with early inflammatory arthritis (IA).Methods.: From the nationwide register maintained by the Social Insurance Institution of Finland, we collected all incident adult patients with newly onset seropositive and seronegative rheumatoid arthritis (RA+ and RA–) and undifferentiated arthritis (UA) between 2010 and 2014. For each case, 3 general population (GP) controls were matched according to age, sex, and place of residence. Drug purchases between 2009 and 2015 were evaluated 1 year before and after the index date (date of IA diagnosis), further dividing this time into 3-month periods.Results.: A total of 12,115 patients (66% women) were identified. At least 1 opioid purchase was done by 23–27% of the patients 1 year before and 15–20% one year after the index date. Relative risk (RR) of opioid purchases compared to GP was highest during the last 3-month time period before the index date [RR 2.81 (95% CI 2.55–3.09), 3.06 (2.68-3.49), and 4.04 (3.51–4.65) for RA+, RA–, and UA, respectively] but decreased after the index date [RR 1.38 (1.23–1.58), 1.91 (1.63–2.24), and 2.51 (2.15–2.93)]. Up to 4% of the patients were longterm users both before and after the diagnosis.Conclusion.: During 2009–15 in Finland, opioid use peaked just before the diagnosis of IA but decreased rapidly after that, suggesting effective disease control, especially in seropositive RA. Further, opioids were used to treat arthritis pain of patients with incident RA and UA less often than previously reported from other countries.


  • Increasing incidence and shifting profile of idiopathic inflammatory rheumatic diseases in adults during this millennium

    by Paula Muilu, Vappu Rantalaiho, Hannu Kautiainen, Lauri Juhani Virta, Johan Gunnar Eriksson, Kari Puolakka

    To explore the trends in the incidence of idiopathic inflammatory rheumatic diseases (IIRDs) after the turn of the millennium. From a nationwide register maintained by the Social Insurance Institution of Finland, we collected all adult patients with IIRDs granted a new special reimbursement for anti-rheumatic drugs between 2000 and 2014. Temporal trends in the incidences of various IIRDs were estimated in three 5-year intervals. A total of 58,405 adult patients were identified. Between 2000–2004 and 2010–2014, the age-adjusted incidence rate of IIRDs increased from 114 to 116/100000 [incidence rate ratio (IRR) 1.03 (95% CI 1.01 to 1.06)] in women and from 67 to 69/100,000 [IRR 1.10 (95% CI 1.06–1.14)] in men. The incidence of seropositive rheumatoid arthritis (RA) remained stable while that of seronegative RA decreased. For other diagnoses, the incidences either increased (unspecified arthritis, psoriatic arthritis, spondyloarthritis), remained stable (reactive arthritis), or decreased (SLE and the group of diseases with the ICD-10 code M35). The gender difference in spondyloarthritis leveled as the incidence in women increased at a higher rate than in men. Mean age at IIRD diagnosis decreased among women. The total age-adjusted incidence of IIRDs has gradually increased, due to the increase in unspecified arthritis, psoriatic arthritis, and spondyloarthritis. This, in addition to the ascending number of individuals at risk in the population, translates into a growing burden to the health care system.